Howe & Rusling Inc. Has $486,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Howe & Rusling Inc. grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.4% in the third quarter, Holdings Channel reports. The institutional investor owned 462 shares of the biopharmaceutical company’s stock after acquiring an additional 15 shares during the period. Howe & Rusling Inc.’s holdings in Regeneron Pharmaceuticals were worth $486,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Strategy Asset Managers LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $576,000. PNC Financial Services Group Inc. grew its holdings in Regeneron Pharmaceuticals by 0.8% during the third quarter. PNC Financial Services Group Inc. now owns 18,325 shares of the biopharmaceutical company’s stock worth $19,264,000 after buying an additional 153 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at $3,532,000. Fifth Third Wealth Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 27.0% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 504 shares of the biopharmaceutical company’s stock valued at $530,000 after acquiring an additional 107 shares in the last quarter. Finally, Prospera Financial Services Inc purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $778,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Down 0.2 %

NASDAQ:REGN opened at $743.35 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $736.01 and a 1 year high of $1,211.20. The stock’s fifty day moving average price is $961.76 and its two-hundred day moving average price is $1,030.14. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market cap of $81.69 billion, a P/E ratio of 18.40, a P/E/G ratio of 2.81 and a beta of 0.15.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a report on Friday, November 1st. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Piper Sandler cut their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Citigroup assumed coverage on Regeneron Pharmaceuticals in a research report on Thursday, November 14th. They set a “neutral” rating and a $895.00 price target for the company. Finally, JPMorgan Chase & Co. cut their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,099.55.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.